张玉, 王伯豪, 华子春. aroC基因在溶瘤菌VNP20009的抗肿瘤疗效和肿瘤靶向性中的作用J. 药学学报, 2025, 60(7): 2218-2226. DOI: 10.16438/j.0513-4870.2025-0270
引用本文: 张玉, 王伯豪, 华子春. aroC基因在溶瘤菌VNP20009的抗肿瘤疗效和肿瘤靶向性中的作用J. 药学学报, 2025, 60(7): 2218-2226. DOI: 10.16438/j.0513-4870.2025-0270
ZHANG Yu, WANG Bo-hao, HUA Zi-chun. Role of aroC in mediating anti-tumor efficacy and tumor targeting of engineered Salmonella VNP20009J. Acta Pharmaceutica Sinica, 2025, 60(7): 2218-2226. DOI: 10.16438/j.0513-4870.2025-0270
Citation: ZHANG Yu, WANG Bo-hao, HUA Zi-chun. Role of aroC in mediating anti-tumor efficacy and tumor targeting of engineered Salmonella VNP20009J. Acta Pharmaceutica Sinica, 2025, 60(7): 2218-2226. DOI: 10.16438/j.0513-4870.2025-0270

aroC基因在溶瘤菌VNP20009的抗肿瘤疗效和肿瘤靶向性中的作用

Role of aroC in mediating anti-tumor efficacy and tumor targeting of engineered Salmonella VNP20009

  • 摘要: 抗肿瘤活体微生物药物研发是当前肿瘤免疫治疗的一个新热点。减毒沙门氏菌VNP20009是研究和应用较多的一株溶瘤菌株。该菌株具有显著的肿瘤靶向性, 其在肿瘤组织分布滴度高于正常组织103~104倍, 同时具有较好的抗肿瘤活性。迄今为止, 其肿瘤靶向性和抗肿瘤活性的分子机制尚为未知, 因而阻碍了该菌株的进一步改造和提升。芳香族氨基酸是细菌生长的必需营养底物, 其合成在沙门氏菌中主要由aroC基因调控。为了探讨芳香族氨基酸合成途径在减毒沙门氏菌VNP20009抗肿瘤活性中的作用, 本研究借助CRISPR/Cas9技术构建了aroC基因缺失的VNP20009 ΔaroC菌株(VNP ΔaroC), 并检测了aroC基因缺失对VNP20009在体外对不同胁迫条件(pH、H2O2) 的耐受能力、侵袭黑色素瘤B16F10肿瘤细胞的能力及其在肿瘤细胞的增殖能力, 以及在黑色素瘤B16F10肿瘤模型上的抗肿瘤药效及组织分布的影响。实验结果表明, VNP ΔaroC菌株在不同pH、H2O2浓度下的生长曲线与野生型菌株VNP20009相比无显著差异, 但其在不同pH、H2O2浓度固体培养基中的菌落生长速率较VNP20009显著降低。此外, VNP ΔaroC对黑色素瘤B16F10细胞的侵袭及增殖能力较VNP20009显著减弱。小鼠肿瘤模型中, VNP ΔaroC菌株的体内毒性显著降低, 但其抗肿瘤能力和肿瘤靶向性也显著减弱。结果表明, aroC是减毒沙门氏菌VNP20009的抗肿瘤疗效和肿瘤靶向性的关键基因。本研究为溶瘤菌VNP20009的进一步合成生物改造做了有益的探索。所有动物实验均经过南京大学动物管理与使用委员会的审查批准(批准号: IACUC-2003167)。

     

    Abstract: The development of antitumor live microbial agents represents an emerging frontier in cancer immunotherapy. Attenuated Salmonella VNP20009 stands as one of the most extensively studied oncolytic bacterial strains, demonstrating remarkable tumor-targeting specificity with 10³–10⁴-fold higher distribution titers in tumor tissues compared to normal tissues, alongside significant antitumor efficacy. However, the molecular mechanisms underlying its tumor-targeting properties and antitumor activity remain elusive, hindering further strain optimization. As aromatic amino acids serve as essential nutrients for bacterial growth, their biosynthesis in Salmonella is primarily regulated by the aroC gene. To investigate the role of aromatic amino acid biosynthesis in VNP20009's antitumor activity, we constructed an aroC-deficient strain (VNP ΔaroC) using CRISPR/Cas9 technology. Systematic evaluations were performed to assess: ① tolerance to extracellular stresses (pH, H2O2) in vitro; ② invasive capacity against B16F10 melanoma cells; ③ proliferative capacity within tumor cells; ④ antitumor efficacy and biodistribution in B16F10 tumor-bearing mice. Experimental results revealed that VNP ΔaroC exhibited comparable growth profiles to wild-type VNP20009 under varying pH and H2O2 conditions. However, its colony growth rate on solid medium under identical pH and H2O2 conditions was significantly reduced relative to VNP20009. Furthermore, the invasive and proliferative capacities against B16F10 melanoma cells were markedly diminished compared to the wild-type strain. In murine models, VNP ΔaroC demonstrated reduced systemic toxicity but concurrently showed attenuated antitumor efficacy and tumor-targeting specificity. These findings establish aroC as a critical gene governing both therapeutic potency and tumor-targeting capability of VNP20009. This study provides valuable insights for further synthetic biological engineering of oncolytic bacterial strains. All animal experiments were approved by the Institutional Animal Care and Use Committee of the Nanjing University (approval No: IACUC-2003167).

     

/

返回文章
返回